PLT012

DB23610InvestigationalProtein Based Therapies

PLT012 is a humanized anti-CD36 antibody developed by Pilatus Biosciences for treating liver cancer and intrahepatic bile duct cancer.

Mechanism: Pharmacologically active on Platelet glycoprotein 4
Curator reviewed
Code names: PLT-012

Resolves to

Targets

What you can answer from here — as of July 02, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with PLT012, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.